{
    "nct_id": "NCT06578247",
    "official_title": "Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia",
    "inclusion_criteria": "* Must be competent and able to comprehend, sign, and date an Ethics Committee (EC)- or Institutional Review Board (IRB)-approved Informed Consent Form (ICF) before performance of any trial-specific procedures or tests.\n* ≥18 years or the minimum legal adult age (whichever is greater) and 70 years (at Screening).\n* Newly diagnosed, morphologically documented primary AML based on the World Health Organization (WHO) 2016 classification (at Screening)\n* Eastern Cooperative Oncology Group (ECOG) performance status (at the time the participant signs their ICF) of 0-2.\n* Participant is receiving standard \"7+3\" induction chemotherapy regimen as specified in the protocol\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).\n* Diagnosis of AML secondary to prior chemotherapy or radiotherapy for other neoplasms or autoimmune/rheumatologic conditions.\n* Diagnosis of AML secondary to myelodysplastic syndrome (MDS) or a myeloproliferative neoplasm (MPN) or MDS/MPNs including CMML, aCML, JMML and others.\n* Participants with newly diagnosed AML with FLT3-ITD mutations (FLT3-ITD [+]) present at ≥5% VAF (or ≥0.05 SR) based on a validated FLT3 mutation assay.\n* Prior treatment for AML, except for the following allowances:\n\n  1. Leukapheresis;\n  2. Treatment for hyperleukocytosis with hydroxyurea;\n  3. Cranial radiotherapy for central nervous system (CNS) leukostasis;\n  4. Prophylactic intrathecal chemotherapy;\n  5. Growth factor/cytokine support.",
    "miscellaneous_criteria": "Key"
}